Literature DB >> 20031565

HFE C282Y homozygosity is associated with lower total and low-density lipoprotein cholesterol: The hemochromatosis and iron overload screening study.

Paul C Adams1, James S Pankow, James C Barton, Ron T Acton, Cathie Leiendecker-Foster, Gordon D McLaren, Mark Speechley, John H Eckfeldt.   

Abstract

BACKGROUND: Previous studies have suggested a positive association of coronary heart disease risk and both serum ferritin concentrations and C282Y heterozygosity. Relationships between serum lipids, C282Y homozygosity, and serum ferritin have not been well established. METHODS AND
RESULTS: The Hemochromatosis and Iron Overload Screening study screened 101 168 participants in primary care from 5 field centers in the United States and Canada with serum ferritin, transferrin saturation, and HFE genotyping for C282Y and H63D mutations. Serum lipids were measured in a subset of 176 C282Y homozygotes (63 male, 113 female whites) without a prior diagnosis of, family history, or treatment for hemochromatosis and a matched sample of participants with normal transferrin saturation and serum ferritin without C282Y or H63D mutations (wild-type, 123 male, 189 female whites). The proportion of subjects who reported using prescription cholesterol-lowering medications was approximately 3 times higher in HFE wild-type subjects than C282Y homozygotes among men (22% versus 7%; P=0.02) and, in women, 2 times higher (16% versus 8%; P=0.07). After excluding subjects taking cholesterol medications, C282Y homozygotes had significantly lower mean total and low-density lipoprotein cholesterol concentrations than wild-type subjects, with larger genotypic differences for low-density lipoprotein in men (-0.62 mmol/L; 95% CI, -0.93 to -0.33) than in women (-0.28 mmol/L; 95%, CI -0.52 to -0.08).
CONCLUSIONS: Total mean serum cholesterol and low-density lipoprotein levels were lower in C282Y homozygotes than in HFE wild-type participants. Further studies are required to determine whether this is related to iron overload, HFE alleles, or other factors on C282Y-positive chromosome 6p haplotypes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20031565     DOI: 10.1161/CIRCGENETICS.108.813089

Source DB:  PubMed          Journal:  Circ Cardiovasc Genet        ISSN: 1942-3268


  11 in total

1.  Hepcidin Deficiency Protects Against Atherosclerosis.

Authors:  Rajeev Malhotra; Florian Wunderer; Hanna J Barnes; Aranya Bagchi; Mary D Buswell; Caitlin D O'Rourke; Charles L Slocum; Clara D Ledsky; Kathryn M Peneyra; Haakon Sigurslid; Benjamin Corman; Kimberly B Johansson; David K Rhee; Kenneth D Bloch; Donald B Bloch
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-02       Impact factor: 8.311

2.  Hereditary hemochromatosis: insights from the Hemochromatosis and Iron Overload Screening (HEIRS) Study.

Authors:  Gordon D McLaren; Victor R Gordeuk
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2009

3.  Genetic determinants for body iron store and type 2 diabetes risk in US men and women.

Authors:  Meian He; Tsegaselassie Workalemahu; JoAnn E Manson; Frank B Hu; Lu Qi
Journal:  PLoS One       Date:  2012-07-16       Impact factor: 3.240

4.  HFE H63D polymorphism as a modifier of the effect of cumulative lead exposure on pulse pressure: the Normative Aging Study.

Authors:  Aimin Zhang; Sung Kyun Park; Robert O Wright; Marc G Weisskopf; Bhramar Mukherjee; Huiling Nie; David Sparrow; Howard Hu
Journal:  Environ Health Perspect       Date:  2010-05-14       Impact factor: 9.031

5.  Genetic colocalization atlas points to common regulatory sites and genes for hematopoietic traits and hematopoietic contributions to disease phenotypes.

Authors:  Christopher S Thom; Benjamin F Voight
Journal:  BMC Med Genomics       Date:  2020-06-29       Impact factor: 3.063

6.  Common conditions associated with hereditary haemochromatosis genetic variants: cohort study in UK Biobank.

Authors:  Luke C Pilling; Jone Tamosauskaite; Garan Jones; Andrew R Wood; Lindsay Jones; Chai-Ling Kuo; George A Kuchel; Luigi Ferrucci; David Melzer
Journal:  BMJ       Date:  2019-01-16

Review 7.  Clinical penetrance in hereditary hemochromatosis: estimates of the cumulative incidence of severe liver disease among HFE C282Y homozygotes.

Authors:  Scott D Grosse; Lyle C Gurrin; Nadine A Bertalli; Katrina J Allen
Journal:  Genet Med       Date:  2017-08-03       Impact factor: 8.822

8.  C282Y-HFE gene variant affects cholesterol metabolism in human neuroblastoma cells.

Authors:  Fatima Ali-Rahmani; Michael A Huang; C-L Schengrund; James R Connor; Sang Y Lee
Journal:  PLoS One       Date:  2014-02-12       Impact factor: 3.240

9.  Replication and Characterization of Association between ABO SNPs and Red Blood Cell Traits by Meta-Analysis in Europeans.

Authors:  Stela McLachlan; Claudia Giambartolomei; Jon White; Pimphen Charoen; Andrew Wong; Chris Finan; Jorgen Engmann; Tina Shah; Micha Hersch; Clara Podmore; Alana Cavadino; Barbara J Jefferis; Caroline E Dale; Elina Hypponen; Richard W Morris; Juan P Casas; Meena Kumari; Yoav Ben-Shlomo; Tom R Gaunt; Fotios Drenos; Claudia Langenberg; Diana Kuh; Mika Kivimaki; Rico Rueedi; Gerard Waeber; Aroon D Hingorani; Jacqueline F Price; Ann P Walker
Journal:  PLoS One       Date:  2016-06-09       Impact factor: 3.240

Review 10.  Non-Transferrin-Bound Iron in the Spotlight: Novel Mechanistic Insights into the Vasculotoxic and Atherosclerotic Effect of Iron.

Authors:  Francesca Vinchi
Journal:  Antioxid Redox Signal       Date:  2021-03-22       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.